Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux: Alexandre Mérieux, Pierre Boulud

BioMérieux has altered its governance to separate the functions of chairman and CEO.

The firm has appointed current Chief Operating Officer Pierre Boulud as CEO, effective July 1. The current Chairman and CEO, Alexandre Mérieux, will assume the role of executive chairman with extended responsibilities and focus on developing the firm's global strategy. Boulud joined the company in 2016 and has served as COO for the past three years. Mérieux joined BioMérieux in 2005 and became CEO in 2017.

The change in governance was proposed by Mérieux and approved by BioMérieux's board of directors on June 13.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.